Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s shares closed last Friday ...

Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit ...

Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in the United States, ...

The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly ...

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...

In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) – Investment analysts at Zacks Research lifted their FY2024 ...

Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns ...

On October 31, 2024, the European Commission issued a fine of €462.6 million to Teva Pharmaceuticals, citing abuse of its ...

TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the ...

Teva Pharmaceutical Industries Ltd. has been fined nearly €463 million ($503 million) by the European Union’s antitrust ...